Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H29FO5 |
Molecular Weight | 392.4611 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]3(F)[C@@]2([H])CCC4=CC(=O)C=C[C@]34C
InChI
InChIKey=UREBDLICKHMUKA-DVTGEIKXSA-N
InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1
DescriptionSources: https://www.drugbank.ca/drugs/DB00443
Sources: https://www.drugbank.ca/drugs/DB00443
Betamethasone and its derivatives, betamethasone sodium phosphate and betamethasone acetate, are synthetic glucocorticoids. Used for its antiinflammatory or immunosuppressive properties, betamethasone is combined with a mineralocorticoid to manage adrenal insufficiency and is used in the form of betamethasone benzoate, betamethasone dipropionate, or betamethasone valerate for the treatment of inflammation due to corticosteroid-responsive dermatoses. Betamethasone and clotrimazole are used together to treat cutaneous tinea infections. Betamethasone is a glucocorticoid receptor agonist. This leads to changes in genetic expression once this complex binds to the GRE. The antiinflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. Betamethasone binds to plasma transcortin, and it becomes active when it is not bound to transcortin.Betamethasone is used for: treating certain conditions associated with decreased adrenal gland function. It is used to treat severe inflammation caused by certain conditions, including severe asthma, severe allergies, rheumatoid arthritis, ulcerative colitis, certain blood disorders, lupus, multiple sclerosis, and certain eye and skin conditions.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2034 |
1.3 nM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | CELESTONE SOLUSPAN Approved UseWhen oral therapy is not feasible, the intramuscular use
of CELESTONE SOLUSPAN Injectable Suspension is indicated as follows:
Allergic States Control of severe or incapacitating allergic conditions intractable to
adequate trials of conventional treatment in asthma, atopic dermatitis, contact
dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum
sickness, transfusion reactions.
Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma,
mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson
syndrome).
Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with
cancer, nonsuppurative thyroiditis.
Gastrointestinal Diseases To tide the patient over a critical period of the disease in
regional enteritis and ulcerative colitis.
Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan
anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia.
Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous
meningitis with subarachnoid block or impending block when used with appropriate
antituberculous chemotherapy.
Neoplastic Diseases For palliative management of leukemias and lymphomas.
Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated
with primary or metastatic brain tumor or craniotomy.
Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular
inflammatory conditions unresponsive to topical corticosteroids.
Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic
syndrome or that due to lupus erythematosus.
Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis
when used concurrently with appropriate antituberculous chemotherapy, idiopathic
eosinophilic pneumonias, symptomatic sarcoidosis.
Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the
patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic
carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile
rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For
the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Launch Date1961 |
|||
Primary | CELESTONE SOLUSPAN Approved UseWhen oral therapy is not feasible, the intramuscular use
of CELESTONE SOLUSPAN Injectable Suspension is indicated as follows:
Allergic States Control of severe or incapacitating allergic conditions intractable to
adequate trials of conventional treatment in asthma, atopic dermatitis, contact
dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum
sickness, transfusion reactions.
Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma,
mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson
syndrome).
Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with
cancer, nonsuppurative thyroiditis.
Gastrointestinal Diseases To tide the patient over a critical period of the disease in
regional enteritis and ulcerative colitis.
Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan
anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia.
Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous
meningitis with subarachnoid block or impending block when used with appropriate
antituberculous chemotherapy.
Neoplastic Diseases For palliative management of leukemias and lymphomas.
Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated
with primary or metastatic brain tumor or craniotomy.
Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular
inflammatory conditions unresponsive to topical corticosteroids.
Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic
syndrome or that due to lupus erythematosus.
Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis
when used concurrently with appropriate antituberculous chemotherapy, idiopathic
eosinophilic pneumonias, symptomatic sarcoidosis.
Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the
patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic
carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile
rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For
the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Launch Date1961 |
|||
Primary | CELESTONE SOLUSPAN Approved UseWhen oral therapy is not feasible, the intramuscular use
of CELESTONE SOLUSPAN Injectable Suspension is indicated as follows:
Allergic States Control of severe or incapacitating allergic conditions intractable to
adequate trials of conventional treatment in asthma, atopic dermatitis, contact
dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum
sickness, transfusion reactions.
Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma,
mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson
syndrome).
Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with
cancer, nonsuppurative thyroiditis.
Gastrointestinal Diseases To tide the patient over a critical period of the disease in
regional enteritis and ulcerative colitis.
Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan
anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia.
Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous
meningitis with subarachnoid block or impending block when used with appropriate
antituberculous chemotherapy.
Neoplastic Diseases For palliative management of leukemias and lymphomas.
Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated
with primary or metastatic brain tumor or craniotomy.
Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular
inflammatory conditions unresponsive to topical corticosteroids.
Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic
syndrome or that due to lupus erythematosus.
Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis
when used concurrently with appropriate antituberculous chemotherapy, idiopathic
eosinophilic pneumonias, symptomatic sarcoidosis.
Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the
patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic
carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile
rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For
the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Launch Date1961 |
|||
Primary | CELESTONE SOLUSPAN Approved UseWhen oral therapy is not feasible, the intramuscular use
of CELESTONE SOLUSPAN Injectable Suspension is indicated as follows:
Allergic States Control of severe or incapacitating allergic conditions intractable to
adequate trials of conventional treatment in asthma, atopic dermatitis, contact
dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum
sickness, transfusion reactions.
Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma,
mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson
syndrome).
Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with
cancer, nonsuppurative thyroiditis.
Gastrointestinal Diseases To tide the patient over a critical period of the disease in
regional enteritis and ulcerative colitis.
Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan
anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia.
Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous
meningitis with subarachnoid block or impending block when used with appropriate
antituberculous chemotherapy.
Neoplastic Diseases For palliative management of leukemias and lymphomas.
Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated
with primary or metastatic brain tumor or craniotomy.
Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular
inflammatory conditions unresponsive to topical corticosteroids.
Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic
syndrome or that due to lupus erythematosus.
Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis
when used concurrently with appropriate antituberculous chemotherapy, idiopathic
eosinophilic pneumonias, symptomatic sarcoidosis.
Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the
patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic
carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile
rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For
the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Launch Date1961 |
|||
Palliative | CELESTONE SOLUSPAN Approved UseWhen oral therapy is not feasible, the intramuscular use
of CELESTONE SOLUSPAN Injectable Suspension is indicated as follows:
Allergic States Control of severe or incapacitating allergic conditions intractable to
adequate trials of conventional treatment in asthma, atopic dermatitis, contact
dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum
sickness, transfusion reactions.
Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma,
mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson
syndrome).
Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with
cancer, nonsuppurative thyroiditis.
Gastrointestinal Diseases To tide the patient over a critical period of the disease in
regional enteritis and ulcerative colitis.
Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan
anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia.
Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous
meningitis with subarachnoid block or impending block when used with appropriate
antituberculous chemotherapy.
Neoplastic Diseases For palliative management of leukemias and lymphomas.
Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated
with primary or metastatic brain tumor or craniotomy.
Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular
inflammatory conditions unresponsive to topical corticosteroids.
Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic
syndrome or that due to lupus erythematosus.
Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis
when used concurrently with appropriate antituberculous chemotherapy, idiopathic
eosinophilic pneumonias, symptomatic sarcoidosis.
Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the
patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic
carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile
rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For
the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Launch Date1961 |
|||
Primary | CELESTONE SOLUSPAN Approved UseWhen oral therapy is not feasible, the intramuscular use
of CELESTONE SOLUSPAN Injectable Suspension is indicated as follows:
Allergic States Control of severe or incapacitating allergic conditions intractable to
adequate trials of conventional treatment in asthma, atopic dermatitis, contact
dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum
sickness, transfusion reactions.
Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma,
mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson
syndrome).
Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with
cancer, nonsuppurative thyroiditis.
Gastrointestinal Diseases To tide the patient over a critical period of the disease in
regional enteritis and ulcerative colitis.
Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan
anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia.
Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous
meningitis with subarachnoid block or impending block when used with appropriate
antituberculous chemotherapy.
Neoplastic Diseases For palliative management of leukemias and lymphomas.
Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated
with primary or metastatic brain tumor or craniotomy.
Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular
inflammatory conditions unresponsive to topical corticosteroids.
Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic
syndrome or that due to lupus erythematosus.
Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis
when used concurrently with appropriate antituberculous chemotherapy, idiopathic
eosinophilic pneumonias, symptomatic sarcoidosis.
Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the
patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic
carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile
rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For
the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Launch Date1961 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
76.8 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31808984 |
6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered: |
BETAMETHASONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
67.6 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31808984 |
6 mg single, intramuscular dose: 6 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
BETAMETHASONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
101 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6662164/ |
8 mg single, intravenous dose: 8 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
BETAMETHASONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
796 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31808984 |
6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered: |
BETAMETHASONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
811 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31808984 |
6 mg single, intramuscular dose: 6 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
BETAMETHASONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
46.3 μg × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6662164/ |
8 mg single, intravenous dose: 8 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
BETAMETHASONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
13.9 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31808984 |
6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered: |
BETAMETHASONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
10.2 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31808984 |
6 mg single, intramuscular dose: 6 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
BETAMETHASONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
335 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6662164/ |
8 mg single, intravenous dose: 8 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
BETAMETHASONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
36% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6662164/ |
8 mg single, intravenous dose: 8 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
BETAMETHASONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no [IC50 >10 uM] | ||||
no [IC50 >10 uM] | ||||
no [IC50 >10 uM] | ||||
no [IC50 >10 uM] | ||||
no [IC50 >10 uM] | ||||
no [IC50 >10 uM] | ||||
no [IC50 >10 uM] | ||||
no [IC50 >133 uM] | ||||
no [IC50 >133 uM] | ||||
no [IC50 >133 uM] | ||||
no [IC50 >133 uM] | ||||
no | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/22673009/ |
yes | |||
yes | ||||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes | ||||
yes | ||||
yes | yes (co-administration study) Comment: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects. |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Treatment of psoriasis with a new combination of calcipotriol and betamethasone dipropionate: a flow cytometric study. | 2001 |
|
Clinical evaluation of human placental extract (placentrex) in radiation-induced oral mucositis. | 2001 |
|
[Rupture of the Achilles tendon after local steroid injection. Case reports and consequences for treatment]. | 2001 |
|
Effects of endogenous and exogenous glucocorticoids on liver differentiation. | 2001 |
|
Clinical experience with topical calcitriol (1,25-dihydroxyvitamin D3) in psoriasis. | 2001 Apr |
|
Efficacy and tolerance of topical calcitriol 3 microg g(-1) in psoriasis treatment: a review of our experience in Poland. | 2001 Apr |
|
[Analysis of selected parameters of maternal and fetal status during stimulation of fetal lung maturation]. | 2001 Apr |
|
[Dyshidrosis and acral purpura during polymorphic dermatitis in pregnancy: 2 cases]. | 2001 Apr |
|
A topical steroid without an antibiotic cures external otitis efficiently: a study in an animal model. | 2001 Aug |
|
Severe oral manifestations of chronic graft-vs.-host disease. | 2001 Aug |
|
The delivery of topical nasal sprays and drops to the middle meatus: a semiquantitative analysis. | 2001 Aug |
|
Single versus repeated-course antenatal corticosteroids: outcomes in singleton and multiple-gestation pregnancies. | 2001 Aug |
|
Most patients overdose on topical nasal corticosteroid drops: an accurate delivery device is required. | 2001 Aug |
|
Infantile acute hemorrhagic edema of the skin. | 2001 Aug |
|
Multiple courses of antenatal betamethasone and cognitive development of mice offspring. | 2001 Aug |
|
Painless thyroiditis induced by the cessation of betamethasone. | 2001 Aug |
|
Evaluation of the inhibitory activity of topical indomethacin, betamethasone valerate and emollients on UVL-induced inflammation by means of non-invasive measurements of the skin elasticity. | 2001 Aug |
|
Repeated prenatal corticosteroid administration delays astrocyte and capillary tight junction maturation in fetal sheep. | 2001 Aug |
|
Differentiation between dexamethasone and betamethasone in a mixture using multiple mass spectrometry. | 2001 Aug 10 |
|
Comparative effects of calcipotriol and betamethasone 17-valerate solution in the treatment of seborrhoeic dermatitis of the scalp. | 2001 Jan |
|
Topical therapy with fluorinated and non-fluorinated corticosteroids in patients with atopic dermatitis. | 2001 Jan |
|
Systemic ketoconazole for yeast allergic patients with atopic dermatitis. | 2001 Jan |
|
Severe vulvovaginitis associated with intravaginal nystatin therapy. | 2001 Jul |
|
An evidence-based assessment of occlusal adjustment as a treatment for temporomandibular disorders. | 2001 Jul |
|
Nonoperative treatment of an interosseous ganglion cyst. | 2001 Jul |
|
Valsalva retinopathy-like hemorrhage associated with combined trabeculotomy-trabeculectomy in a patient with developmental glaucoma. | 2001 Jul-Aug |
|
Tocolytic magnesium sulfate toxicity and unexpected neonatal death. | 2001 Jun |
|
Deleterious effects of local corticosteroid injections on the Achilles tendon of rats. | 2001 Jun |
|
Preliminary results of a pilot study investigating the potential of salivary cortisol measurements to detect occult adrenal suppression secondary to steroid nose drops. | 2001 Jun |
|
Inhibitory effects of anti-inflammatory drugs on interleukin-6 bioactivity. | 2001 Jun |
|
A prospective, randomized trial comparing the efficacy of dexamethasone and betamethasone for the treatment of antepartum HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome. | 2001 Jun |
|
Tacrolimus suppressed the production of cytokines involved in atopic dermatitis by direct stimulation of human PBMC system. (Comparison with steroids). | 2001 Jun |
|
Treatment of de Quervain's disease:role of conservative management. | 2001 Jun |
|
Dose dependent increased mortality risk in COPD patients treated with oral glucocorticoids. | 2001 Mar |
|
Investigation of some commercially available spacer devices for the delivery of glucocorticoid steroids from a pMDI. | 2001 May |
|
[Pemphigoid gestationis: treatment by topical class I corticosteroid]. | 2001 May |
|
Dermatitis during radiation for vulvar carcinoma: prevention and treatment with granulocyte-macrophage colony-stimulating factor impregnated gauze. | 2001 May-Jun |
|
Comparison of intramuscular betamethasone and oral prednisone in the prevention of relapse of acute asthma. | 2001 May-Jun |
|
Lumbar facet joint synovial cyst: percutaneous treatment with steroid injections and distention--clinical and imaging follow-up in 12 patients. | 2001 Oct |
|
Use of antenatal steroids to counteract the negative effects of tracheal occlusion in the fetal lamb model. | 2001 Oct |
|
Antenatal corticosteroids-too much of a good thing? | 2001 Oct 3 |
|
Single vs weekly courses of antenatal corticosteroids for women at risk of preterm delivery: A randomized controlled trial. | 2001 Oct 3 |
|
Growth and development of children to 4 years of age after repeated antenatal steroid administration. | 2001 Sep |
|
Repeated antenatal corticosteroid treatments. Do they reduce neonatal morbidity? | 2001 Sep |
|
Effects of antiinflammatory drugs on migration of the rabbit corneal epithelium. | 2001 Sep |
|
Manipulation under anesthesia for frozen shoulder with and without steroid injection. | 2001 Sep |
|
Multiple courses of antenatal steroids: risks and benefits. | 2001 Sep |
|
Fetal monkey surfactants after intra-amniotic or maternal administration of betamethasone and thyroid hormone. | 2001 Sep |
|
Treatment of childhood phimosis with a moderately potent topical steroid. | 2001 Sep |
|
Programming effects in sheep of prenatal growth restriction and glucocorticoid exposure. | 2001 Sep |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/betamethasone-sodium-phosphate-and-betamethasone-acetate.html
Curator's Comment: Can also be used topically https://medlineplus.gov/druginfo/meds/a682799.html
The initial dosage of parenterally administered Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may vary from 0.25 to 9 mg per day depending on the specific disease entity being treated. However, in certain overwhelming, acute, life-threatening situations, administrations in dosages exceeding the usual dosages may be justified and may be in multiples of the oral dosages. In the treatment of acute exacerbations of multiple sclerosis, daily doses of 30 mg of betamethasone for a week followed by 12 mg every other day for 1 month are recommended.In pediatric patients, the initial dose of betamethasone may vary depending on the specific disease entity being treated. The range of initial doses is 0.02 to 0.3 mg/kg/day in three or four divided doses (0.6 to 9 mg/m2bsa/day).
Route of Administration:
Parenteral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9751455
Betamethasone (10(-6)M) significantly reduced both pH 6-induced bronchial response and CGRP-like immunoreactivity overflow in guinea-pig isolated perfused lung.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QS03BA03
Created by
admin on Fri Dec 15 15:12:59 GMT 2023 , Edited by admin on Fri Dec 15 15:12:59 GMT 2023
|
||
|
CFR |
21 CFR 524.1044D
Created by
admin on Fri Dec 15 15:12:58 GMT 2023 , Edited by admin on Fri Dec 15 15:12:58 GMT 2023
|
||
|
CFR |
21 CFR 524.1044I
Created by
admin on Fri Dec 15 15:12:58 GMT 2023 , Edited by admin on Fri Dec 15 15:12:58 GMT 2023
|
||
|
WHO-ATC |
R03BA04
Created by
admin on Fri Dec 15 15:12:58 GMT 2023 , Edited by admin on Fri Dec 15 15:12:58 GMT 2023
|
||
|
CFR |
21 CFR 524.1044B
Created by
admin on Fri Dec 15 15:12:58 GMT 2023 , Edited by admin on Fri Dec 15 15:12:58 GMT 2023
|
||
|
WHO-VATC |
QA07EA04
Created by
admin on Fri Dec 15 15:12:59 GMT 2023 , Edited by admin on Fri Dec 15 15:12:59 GMT 2023
|
||
|
WHO-ATC |
D07AC01
Created by
admin on Fri Dec 15 15:12:58 GMT 2023 , Edited by admin on Fri Dec 15 15:12:58 GMT 2023
|
||
|
FDA ORPHAN DRUG |
492415
Created by
admin on Fri Dec 15 15:12:59 GMT 2023 , Edited by admin on Fri Dec 15 15:12:59 GMT 2023
|
||
|
NDF-RT |
N0000175576
Created by
admin on Fri Dec 15 15:12:59 GMT 2023 , Edited by admin on Fri Dec 15 15:12:59 GMT 2023
|
||
|
WHO-VATC |
QD07BC01
Created by
admin on Fri Dec 15 15:12:59 GMT 2023 , Edited by admin on Fri Dec 15 15:12:59 GMT 2023
|
||
|
WHO-ATC |
D07CC01
Created by
admin on Fri Dec 15 15:12:58 GMT 2023 , Edited by admin on Fri Dec 15 15:12:58 GMT 2023
|
||
|
WHO-ATC |
S01BB04
Created by
admin on Fri Dec 15 15:12:58 GMT 2023 , Edited by admin on Fri Dec 15 15:12:58 GMT 2023
|
||
|
WHO-VATC |
QD07CC01
Created by
admin on Fri Dec 15 15:12:59 GMT 2023 , Edited by admin on Fri Dec 15 15:12:59 GMT 2023
|
||
|
NDF-RT |
N0000175450
Created by
admin on Fri Dec 15 15:12:59 GMT 2023 , Edited by admin on Fri Dec 15 15:12:59 GMT 2023
|
||
|
WHO-VATC |
QR03BA04
Created by
admin on Fri Dec 15 15:12:59 GMT 2023 , Edited by admin on Fri Dec 15 15:12:59 GMT 2023
|
||
|
WHO-ATC |
S01CA05
Created by
admin on Fri Dec 15 15:12:58 GMT 2023 , Edited by admin on Fri Dec 15 15:12:58 GMT 2023
|
||
|
WHO-VATC |
QS02CA90
Created by
admin on Fri Dec 15 15:12:59 GMT 2023 , Edited by admin on Fri Dec 15 15:12:59 GMT 2023
|
||
|
WHO-ATC |
S01CB04
Created by
admin on Fri Dec 15 15:12:58 GMT 2023 , Edited by admin on Fri Dec 15 15:12:58 GMT 2023
|
||
|
WHO-ATC |
A07EA04
Created by
admin on Fri Dec 15 15:12:58 GMT 2023 , Edited by admin on Fri Dec 15 15:12:58 GMT 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
13.3
Created by
admin on Fri Dec 15 15:12:59 GMT 2023 , Edited by admin on Fri Dec 15 15:12:59 GMT 2023
|
||
|
WHO-VATC |
QS01BA06
Created by
admin on Fri Dec 15 15:12:59 GMT 2023 , Edited by admin on Fri Dec 15 15:12:59 GMT 2023
|
||
|
WHO-ATC |
H02AB01
Created by
admin on Fri Dec 15 15:12:58 GMT 2023 , Edited by admin on Fri Dec 15 15:12:58 GMT 2023
|
||
|
WHO-ATC |
S01BA06
Created by
admin on Fri Dec 15 15:12:58 GMT 2023 , Edited by admin on Fri Dec 15 15:12:58 GMT 2023
|
||
|
CFR |
21 CFR 524.1044G
Created by
admin on Fri Dec 15 15:12:58 GMT 2023 , Edited by admin on Fri Dec 15 15:12:58 GMT 2023
|
||
|
WHO-VATC |
QD07XC01
Created by
admin on Fri Dec 15 15:12:59 GMT 2023 , Edited by admin on Fri Dec 15 15:12:59 GMT 2023
|
||
|
WHO-VATC |
QS01CB04
Created by
admin on Fri Dec 15 15:12:59 GMT 2023 , Edited by admin on Fri Dec 15 15:12:59 GMT 2023
|
||
|
WHO-VATC |
QH02AB01
Created by
admin on Fri Dec 15 15:12:59 GMT 2023 , Edited by admin on Fri Dec 15 15:12:59 GMT 2023
|
||
|
CFR |
21 CFR 524.1044F
Created by
admin on Fri Dec 15 15:12:58 GMT 2023 , Edited by admin on Fri Dec 15 15:12:58 GMT 2023
|
||
|
WHO-ATC |
R01AD06
Created by
admin on Fri Dec 15 15:12:58 GMT 2023 , Edited by admin on Fri Dec 15 15:12:58 GMT 2023
|
||
|
WHO-ATC |
D07XC01
Created by
admin on Fri Dec 15 15:12:58 GMT 2023 , Edited by admin on Fri Dec 15 15:12:58 GMT 2023
|
||
|
WHO-VATC |
QC05AA05
Created by
admin on Fri Dec 15 15:12:59 GMT 2023 , Edited by admin on Fri Dec 15 15:12:59 GMT 2023
|
||
|
NCI_THESAURUS |
C521
Created by
admin on Fri Dec 15 15:12:59 GMT 2023 , Edited by admin on Fri Dec 15 15:12:59 GMT 2023
|
||
|
WHO-ATC |
S02BA07
Created by
admin on Fri Dec 15 15:12:58 GMT 2023 , Edited by admin on Fri Dec 15 15:12:58 GMT 2023
|
||
|
WHO-VATC |
QS03CA06
Created by
admin on Fri Dec 15 15:12:59 GMT 2023 , Edited by admin on Fri Dec 15 15:12:59 GMT 2023
|
||
|
WHO-ATC |
D07BC01
Created by
admin on Fri Dec 15 15:12:58 GMT 2023 , Edited by admin on Fri Dec 15 15:12:58 GMT 2023
|
||
|
LIVERTOX |
100
Created by
admin on Fri Dec 15 15:12:59 GMT 2023 , Edited by admin on Fri Dec 15 15:12:59 GMT 2023
|
||
|
WHO-VATC |
QS01BB04
Created by
admin on Fri Dec 15 15:12:59 GMT 2023 , Edited by admin on Fri Dec 15 15:12:59 GMT 2023
|
||
|
WHO-ATC |
S03CA06
Created by
admin on Fri Dec 15 15:12:58 GMT 2023 , Edited by admin on Fri Dec 15 15:12:58 GMT 2023
|
||
|
WHO-ATC |
S03BA03
Created by
admin on Fri Dec 15 15:12:58 GMT 2023 , Edited by admin on Fri Dec 15 15:12:58 GMT 2023
|
||
|
WHO-VATC |
QD07AC01
Created by
admin on Fri Dec 15 15:12:59 GMT 2023 , Edited by admin on Fri Dec 15 15:12:59 GMT 2023
|
||
|
WHO-VATC |
QS01CA05
Created by
admin on Fri Dec 15 15:12:59 GMT 2023 , Edited by admin on Fri Dec 15 15:12:59 GMT 2023
|
||
|
WHO-ATC |
C05AA05
Created by
admin on Fri Dec 15 15:12:58 GMT 2023 , Edited by admin on Fri Dec 15 15:12:58 GMT 2023
|
||
|
WHO-VATC |
QR01AD06
Created by
admin on Fri Dec 15 15:12:59 GMT 2023 , Edited by admin on Fri Dec 15 15:12:59 GMT 2023
|
||
|
WHO-VATC |
QS02BA07
Created by
admin on Fri Dec 15 15:12:59 GMT 2023 , Edited by admin on Fri Dec 15 15:12:59 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1514
Created by
admin on Fri Dec 15 15:12:59 GMT 2023 , Edited by admin on Fri Dec 15 15:12:59 GMT 2023
|
PRIMARY | RxNorm | ||
|
3077
Created by
admin on Fri Dec 15 15:12:58 GMT 2023 , Edited by admin on Fri Dec 15 15:12:58 GMT 2023
|
PRIMARY | |||
|
m2452
Created by
admin on Fri Dec 15 15:12:59 GMT 2023 , Edited by admin on Fri Dec 15 15:12:59 GMT 2023
|
PRIMARY | Merck Index | ||
|
D001623
Created by
admin on Fri Dec 15 15:12:59 GMT 2023 , Edited by admin on Fri Dec 15 15:12:59 GMT 2023
|
PRIMARY | |||
|
Betamethasone
Created by
admin on Fri Dec 15 15:12:59 GMT 2023 , Edited by admin on Fri Dec 15 15:12:59 GMT 2023
|
PRIMARY | |||
|
CHEMBL632
Created by
admin on Fri Dec 15 15:12:58 GMT 2023 , Edited by admin on Fri Dec 15 15:12:58 GMT 2023
|
PRIMARY | |||
|
SUB05797MIG
Created by
admin on Fri Dec 15 15:12:58 GMT 2023 , Edited by admin on Fri Dec 15 15:12:58 GMT 2023
|
PRIMARY | |||
|
C303
Created by
admin on Fri Dec 15 15:12:59 GMT 2023 , Edited by admin on Fri Dec 15 15:12:59 GMT 2023
|
PRIMARY | |||
|
100000091947
Created by
admin on Fri Dec 15 15:12:59 GMT 2023 , Edited by admin on Fri Dec 15 15:12:59 GMT 2023
|
PRIMARY | |||
|
BETAMETHASONE
Created by
admin on Fri Dec 15 15:12:59 GMT 2023 , Edited by admin on Fri Dec 15 15:12:59 GMT 2023
|
PRIMARY | Description: A white or creamy white powder; odourless. Solubility: Practically insoluble in water; sparingly soluble in ethanol (~750 g/l) TS. Category: Adrenoglucocorticoid. Storage: Betamethasone should be kept in a tightly closed container, protected from light. Definition: Betamethasone contains not less than 96.0% and not more than 104.0% of C22H29FO5 calculated with reference to the dried substance. | ||
|
BETAMETHASONE
Created by
admin on Fri Dec 15 15:12:59 GMT 2023 , Edited by admin on Fri Dec 15 15:12:59 GMT 2023
|
PRIMARY | |||
|
DTXSID3022667
Created by
admin on Fri Dec 15 15:12:59 GMT 2023 , Edited by admin on Fri Dec 15 15:12:59 GMT 2023
|
PRIMARY | |||
|
3015
Created by
admin on Fri Dec 15 15:12:59 GMT 2023 , Edited by admin on Fri Dec 15 15:12:59 GMT 2023
|
PRIMARY | |||
|
9782
Created by
admin on Fri Dec 15 15:12:59 GMT 2023 , Edited by admin on Fri Dec 15 15:12:59 GMT 2023
|
PRIMARY | |||
|
1045
Created by
admin on Fri Dec 15 15:12:59 GMT 2023 , Edited by admin on Fri Dec 15 15:12:59 GMT 2023
|
PRIMARY | |||
|
Betamethasone, Topical
Created by
admin on Fri Dec 15 15:12:59 GMT 2023 , Edited by admin on Fri Dec 15 15:12:59 GMT 2023
|
PRIMARY | |||
|
378-44-9
Created by
admin on Fri Dec 15 15:12:58 GMT 2023 , Edited by admin on Fri Dec 15 15:12:58 GMT 2023
|
PRIMARY | |||
|
9842X06Q6M
Created by
admin on Fri Dec 15 15:12:59 GMT 2023 , Edited by admin on Fri Dec 15 15:12:59 GMT 2023
|
PRIMARY | |||
|
1066009
Created by
admin on Fri Dec 15 15:12:59 GMT 2023 , Edited by admin on Fri Dec 15 15:12:59 GMT 2023
|
PRIMARY | |||
|
9842X06Q6M
Created by
admin on Fri Dec 15 15:12:58 GMT 2023 , Edited by admin on Fri Dec 15 15:12:58 GMT 2023
|
PRIMARY | |||
|
39470
Created by
admin on Fri Dec 15 15:12:59 GMT 2023 , Edited by admin on Fri Dec 15 15:12:59 GMT 2023
|
PRIMARY | |||
|
DB00443
Created by
admin on Fri Dec 15 15:12:59 GMT 2023 , Edited by admin on Fri Dec 15 15:12:59 GMT 2023
|
PRIMARY | |||
|
206-825-4
Created by
admin on Fri Dec 15 15:12:59 GMT 2023 , Edited by admin on Fri Dec 15 15:12:59 GMT 2023
|
PRIMARY | |||
|
348
Created by
admin on Fri Dec 15 15:12:59 GMT 2023 , Edited by admin on Fri Dec 15 15:12:59 GMT 2023
|
PRIMARY | |||
|
7061
Created by
admin on Fri Dec 15 15:12:59 GMT 2023 , Edited by admin on Fri Dec 15 15:12:59 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)